RE: New Health20 May 2026 07:13
MPAL in my opinion.
The big headline is the £1.3m marketing push. For a company this size, that’s aggressive and suggests management sees a real opportunity to scale recurring GLP-1 revenues fast.
“New Health” is also a much cleaner consumer-facing brand than MedPal AI and the domains:
* new.co.uk
* new.uk
are premium assets for online healthcare marketing.
The oral Wegovy angle could be huge too. If Novo Nordisk gets UK approval for the pill this summer, the addressable market could expand massively beyond people willing to use injections.
Most importantly, MPAL is positioning itself as more than just another online pharmacy:
* AI-assisted intake
* clinician oversight
* NHS-linked dispensing hubs
* automation
* direct Lilly & Novo supply
Starting to look like a scalable digital healthcare platform rather than a typical AIM lifestyle stock.